<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411800</url>
  </required_header>
  <id_info>
    <org_study_id>LX1033.1-103-NRM</org_study_id>
    <secondary_id>LX1033.103</secondary_id>
    <nct_id>NCT01411800</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Two-Way Crossover Study of Two Oral Formulations of LX1033 in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacodynamic effects, pharmacokinetics, and
      safety of two oral formulations (tablet and capsule) of LX1033 in normal healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary 5-HIAA levels</measure>
    <time_frame>34 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma 5-HIAA levels</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum observed plasma concentration occurs</measure>
    <time_frame>32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of the drug in plasma</measure>
    <time_frame>32 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg LX1033, capsules administered two times per day orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg LX1033, tablets administered two times per day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 mg capsule</intervention_name>
    <description>Two 250 mg capsules will be administered for 500 mg dose</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 mg tablets</intervention_name>
    <description>Two 250 mg tablets will be administered for a 500 mg dose</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects age 18 to 55 years

          -  Vital signs acceptable at Screening

          -  Body mass index (BMI) between 18 and 35 kg/m^2 at Screening

          -  Considered to be in good health, as determined by the Investigator

          -  Normal ECG findings

          -  Negative urine screen for drugs of abuse and negative breath test for alcohol

          -  Negative hepatitis B surface antigen, hepatitis C antibody, and HIV1 and HIV2 antibody
             tests within the last 28 days

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Use of any medication (including acetaminophen) within 5 days of dosing

          -  Use of any investigational agent or selective serotonin reuptake inhibitors (SSRIs)
             within 30 days of study start

          -  Administration of any protein or antibodies within 90 days of study start

          -  Donation or loss of greater than 450 mL of blood within 45 days of study start

          -  Known history of hepatic disease or significantly abnormal liver function tests

          -  History of alcoholism or substance abuse within 3 years prior to study start

          -  Participation in any other clinical study within 30 days preceding the first dose of
             study drug

          -  Positive serum pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna Ogbaa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

